Other grades of this product :
| GSK2194069 Basic information |
| Product Name: | GSK2194069 | | Synonyms: | GSK2194069;4-[4-(5-Benzofuranyl)phenyl]-5-[[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl]-2,4-dihydro-3H-1,2,4-triazol-3-one;GSK2194069
(GSK 2194069;3H-1,2,4-Triazol-3-one, 4-[4-(5-benzofuranyl)phenyl]-5-[[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl]-2,4-dihydro-;GSK2194069 >=97% (HPLC);(S)-4-(4-(benzofuran-5-yl)phenyl)-5-((1-(cyclopropanecarbonyl)pyrrolidin-3-yl)methyl)-2,4-dihydro-3H-1,2,4-triazol-3-one | | CAS: | 1332331-08-4 | | MF: | C25H24N4O3 | | MW: | 428.48 | | EINECS: | | Product Categories: | | Mol File: | 1332331-08-4.mol |
| GSK2194069 Chemical Properties |
| density | 1.44±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C | | form | powder | | pka | 6.15±0.20(Predicted) | | color | white to light brown |
| GSK2194069 Usage And Synthesis |
| Uses | GSK 2194069 is a potent human fatty acid synthase (hFASN) inhibitor. | | Biochem/physiol Actions | GSK2194069 is a fatty acid synthase (FAS) inhibitor. GSK2194069 is a potent and specific inhibitor of the β-ketoacyl reductase (KR) activity of hFAS with an IC50 of 7.7 ± 4.1 nM for the overall hFAS reaction. FAS is upregulated in some cancers, including prostate cancer. GSK2194069 was found to inhibit tumour growth in prostate cancer C42b cell xenografts generated in Nod-SCID-gamma mice. Cellular FAS inhibition reduced cell growth were also demonstrated in non-small-cell lung (A549) cancer cell lines with an average EC50 of 15 ± 0.5 nM. |
| GSK2194069 Preparation Products And Raw materials |
|
日本语
한국어
Français
Deutsch
España
Türkiye